CoMind secured $102.5 million in funding to support its non-invasive brain monitoring system.
The London-based company had its latest funding round led by Plural. Existing investors Angelini Ventures, LocalGlobe, Octopus Ventures, Crane, Backed VC and Entrepreneurs First joined as well.
According to a news release, the company plans to use funds to advance regulatory efforts for its first product, CoMind One. It also aims to complete additional clinical trials, expand its team and enter into new manufacturing partnerships.
Related: Hyperfine prices $17.5M offering
CoMind develops a non-invasive brain monitoring system designed to deliver real-time insight into cerebral perfusion, autoregulation and intracranial pressure. The platform uses infrared light technology centered around a simple adhesive sensor. According to the company, the sensor goes on the patient’s forehead, with ease of use and minimal training representing key design goals.
The company hopes to support clinicians with continuous brain physiology signals to inform decision-making across a range of settings. Those include cardiac and vascular surgery, intensive care and traumatic brain injury management. CoMind said its system can display signals on its own display platform or integrate into existing multiparameter monitors. It hopes to support seamless integration into existing clinical workflows.
CoMind says its offering could create an alternative to current brain monitoring options. Such options utilize risky procedures that require drilling into a skull or rely on innacurate non-invasive monitoring, the company says. Its platform delivers critical information about cerebral blood flow, cerebral autoregulation, and intracranial pressure easily and continually at the bed-side. The company says this allows clinicians to make life-saving decisions.
“We’re excited to advance our mission of redefining the way the brain is measured and treated,” CoMind said.
